### Device

**Implantable cardioverter defibrillator (ICD) lead.**  
Sprint Fidelis, model numbers: 6930, 6931, 6948 and 6949  
Manufactured by Medtronic.

### Problem

- Risk of inappropriate shocks and loss of therapy.  
- Increased risk that the high voltage conductor will fracture if the pace-sense conductor has previously fractured in the same lead.

### Action

Identify patients where:

1. the pace-sense conductor has fractured,  
2. a new pace-sense lead has been inserted and  
3. the high voltage conductor remains in use.  

For these patients, consider the need to implant a new high voltage conductor at elective device change, taking into account the age and clinical circumstances of the patient.  

If these patients are at high risk of sudden cardiac death in the event of high voltage conductor failure, then consider elective lead replacement before device change.  

Where a new conductor fracture occurs, implant a new high voltage lead.  

Where a lead is functioning normally, continue with existing patient management recommendations and use of Medtronic Lead Integrity Alert (LIA). This should be done taking into account the recent update in long term lead survival data presented in the Field Safety Notice of April 2011.

### Action by

All cardiologists and cardiac physiologists who manage patients implanted with ICD leads.

### CAS deadlines

**Action underway:** 26 May 2011  
**Action complete:** 22 August 2011

### Contact

**Manufacturer**  
Mrs Lezlie Bridge  
Medtronic  
Tel: 01923 212 213  
Fax: 01923 225 273  
Email: lezlie.j.bridge@medtronic.com
Problem

In March 2009 Medtronic issued a Field Safety Notice (FSN) advising clinicians that one option for dealing with this problem was to implant a new pace-sense lead while maintaining the use of the high voltage conductor.

However, Medtronic estimates that the survival for the Sprint Fidelis high voltage conductor is 77.7% at 21 months if a pace-sense conductor fracture has previously occurred. Therefore, Medtronic no longer recommends this course of action and has issued another FSN (April 2011). All other patient management recommendations in the March 2009 FSN remain unchanged.

Distribution

This MDA has been sent to:
- NHS trusts in England (Chief Executives)
- Care Quality Commission (CQC) (Headquarters) for information
- HSC trusts in Northern Ireland (Chief Executives)
- NHS boards in Scotland (Equipment Co-ordinators)
- NHS boards and trusts in Wales (Chief Executives)
- Primary care trusts in England (Chief Executives)

Onward distribution

Please bring this notice to the attention of relevant employees in your establishment. Below is a suggested list of recipients.

Trusts

CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:
- A&E departments
- Arrhythmia nurses
- Cardiac laboratory technicians
- Cardiac pacing technicians
- Cardiologists
- Cardiology departments
- Cardiology nurses
- Cardiology, directors of
- Clinical governance leads
- Coronary care departments
- Coronary care nurses
- Medical directors
- Risk managers

Independent distribution

Establishments registered with the Care Quality Commission (CQC) (England only)

This alert should be read by:
- Independent treatment centres

Please note: CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health’s Central Alerting System (CAS) by sending an email to: safetyalerts@dh.gsi.gov.uk and requesting this facility.
Contacts

Manufacturer
Mrs Lezlie Bridge
Medtronic Limited
Building 9
Croxley Green Business Park
Hatters Lane
Watford
Hertfordshire
WD18 8WW
Tel: 01923 212 213
Fax: 01923 225 273
Email: lezlie.j.bridge@medtronic.com

England

If you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2011/0051 or 2011/004/004/291/016

Technical aspects
Ms Sam Baxter or Mr Guido Fumagalli
Medicines & Healthcare products Regulatory Agency
Floor 4
151 Buckingham Palace Road
London SW1W 9SZ
Tel: 020 3080 7242 / 7144
Fax: 020 8754 3965
Email: sam.baxter@mhra.gsi.gov.uk
guido.fumagalli@mhra.gsi.gov.uk

Clinical aspects
Dr Nicola Lennard
Medicines & Healthcare products Regulatory Agency
Floor 4
151 Buckingham Palace Road
London SW1W 9SZ
Tel: 020 3080 7126
Fax: 020 8754 3965
Email: nicola.lennard@mhra.gsi.gov.uk

How to report adverse incidents
Please report via our website http://www.mhra.gov.uk
Further information about CAS can be found at https://www.cas.dh.gov.uk/Home.aspx
Northern Ireland

Alerts in Northern Ireland will continue to be distributed via the NI SABS system.

Enquiries and adverse incident reports in Northern Ireland should be addressed to:

Northern Ireland Adverse Incident Centre
Health Estates Investment Group
Room 17
Annex 6
Castle Buildings
Stormont Estate
Dundonald BT4 3SQ
Tel: 02890 523 704
Fax: 02890 523 900
Email: NIAIC@dhsspsni.gov.uk
http://www.dhsspsni.gov.uk/index/hea/niaic.htm

How to report adverse incidents in Northern Ireland

Please report directly to NIAIC, further information can be found on our website http://www.dhsspsni.gov.uk/niaic
Further information about SABS can be found at http://sabs.dhsspsni.gov.uk/

Scotland

Enquiries and adverse incident reports in Scotland should be addressed to:

Incident Reporting and Investigation Centre
Health Facilities Scotland
NHS National Services Scotland
Gyle Square
1 South Gyle Crescent
Edinburgh EH12 9EB
Tel: 0131 275 7575
Fax: 0131 314 0722
Email: nss.iric@nhs.net

Wales

Enquiries in Wales should be addressed to:

Dr Sara Hayes
Senior Medical Officer
Medical Device Alerts
Welsh Assembly Government
Cathays Park
Cardiff CF10 3NQ
Tel: 029 2082 3922
Email: Haz-Aic@wales.gsi.gov.uk

MHRA is an executive agency of the Department of Health
© Crown Copyright 2011
Addressees may take copies for distribution within their own organisations